Insights

Strategic funding Mitochon has secured a meaningful grant from The ALS Association totaling one million dollars to support a Phase 2 trial for MP-101 in ALS, indicating validated interest from patient advocacy groups and potential co-investment leverage for future programs.

ALS focus Recent grant activity tied to ALS and the planned early 2027 Phase 2 trial suggests a near-term commercial and partnering window around MP-101 for ALS, making this program a primary BD target with clear milestones.

Mitochondrial platform The company’s mitochondria-targeted oral brain therapies offer a distinctive mechanism aimed at multiple neurodegenerative diseases, presenting cross-disease collaboration opportunities with firms pursuing Huntington’s, MS, ALS, AD, PD and TBI indications.

Orphan and advocacy signals Orphan Drug Designation awarded for MP-101 in Huntington’s Disease and MJFF support for Parkinson’s research highlight regulatory and advocacy signals that can de-risk partnerships and attract interested sponsors seeking accelerated paths.

Strategic partnerships With a small team and revenue in the low millions alongside established relationships (MJFF, ALS Association), there is room for alliance-led deals, co-development, or out-licensing of select programs to larger biotechs or specialty pharma seeking mitochondria-focused assets.

Similar companies to Mitochon Pharmaceuticals, Inc.

Mitochon Pharmaceuticals, Inc. Tech Stack

Mitochon Pharmaceuticals, Inc. uses 8 technology products and services including WordPress, Google Fonts API, Clipboard.js, and more. Explore Mitochon Pharmaceuticals, Inc.'s tech stack below.

  • Content Management System
  • Google Fonts API
    Font Scripts
  • Clipboard.js
    Javascript Libraries
  • Yoast SEO
    Search Engines
  • Google Tag Manager
    Tag Management
  • CivicTheme
    UI Frameworks
  • Video Players

Media & News

Mitochon Pharmaceuticals, Inc.'s Email Address Formats

Mitochon Pharmaceuticals, Inc. uses at least 1 email format:
Mitochon Pharmaceuticals, Inc. Email FormatsExamplePercentage
FLast@mitochonpharma.comJDoe@mitochonpharma.com
100%

Frequently Asked Questions

What is Mitochon Pharmaceuticals, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc.'s official website is mitochonpharma.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Mitochon Pharmaceuticals, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Mitochon Pharmaceuticals, Inc.'s annual revenue is estimated to be $1M - $10M.

What is Mitochon Pharmaceuticals, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mitochon Pharmaceuticals, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Mitochon Pharmaceuticals, Inc. has approximately 4 employees across 2 continents, including North America and Europe. Key team members include Chief Executive Officer And Founder: R. A. and Founder & Cso: J. G. Explore Mitochon Pharmaceuticals, Inc.'s employee directory with LeadIQ.

What industry does Mitochon Pharmaceuticals, Inc. belong to?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc. operates in the Biotechnology Research industry.

What technology does Mitochon Pharmaceuticals, Inc. use?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc.'s tech stack includes WordPress, Google Fonts API, Clipboard.js, Yoast SEO, Google Tag Manager, CivicTheme, Vimeo and DigitalOcean Web Hosting.

What is Mitochon Pharmaceuticals, Inc.'s email format?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc.'s email format typically follows the pattern of FLast@mitochonpharma.com. Find more Mitochon Pharmaceuticals, Inc. email formats with LeadIQ.

How much funding has Mitochon Pharmaceuticals, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2026, Mitochon Pharmaceuticals, Inc. has raised $3.3M in funding. The last funding round occurred on Aug 20, 2026 for $1.6M.

When was Mitochon Pharmaceuticals, Inc. founded?

Minus sign iconPlus sign icon
Mitochon Pharmaceuticals, Inc. was founded in 2014.
Mitochon Pharmaceuticals, Inc. logo

Mitochon Pharmaceuticals, Inc.

Biotechnology ResearchPennsylvania, United States2-10 Employees

Mitochon Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies that target mitochondrial function to address serious diseases with unmet medical needs. Its programs concentrate on neurodegenerative disorders, including Huntington’s disease, multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. The company proposes that mitochondrial dysfunction—leading to oxidative stress, reduced ATP production, calcium overload, and aging-related decline—underpins these conditions and seeks to correct it with brain-penetrant, oral therapies.

Based in Blue Bell, Pennsylvania, the company operates as a small team pursuing clinically staged drug development. Its work sits within the biotechnology research sector and focuses on mitochondrial-targeted compounds as potential disease-modifying options. In recent developments, the FDA granted Orphan Drug Designation for MP-101 for Huntington’s Disease.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
2-10

Section iconFunding & Financials

  • $3.3M

    Mitochon Pharmaceuticals, Inc. has raised a total of $3.3M of funding over 4 rounds. Their latest funding round was raised on Aug 20, 2026 in the amount of $1.6M as a Grant.

  • $1M - $10M

    Mitochon Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.